Inspira Technologies Oxy B.H.N (Nasdaq:IINN) - Aandelenkoers, Nieuws & Analyse

IINN Overzicht aandelen

Inspira Technologies Oxy B.H.N. Ltd., een bedrijf gespecialiseerd in medische apparatuur, houdt zich bezig met onderzoek, ontwikkeling, productie en marketing van eigen life support technologie voor de behandeling van acuut respiratoir falen. Meer informatie

IINN fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

De winst is de afgelopen 5 jaar met 22.3% per jaar gedaald

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

De laatste financiële rapporten zijn ouder dan 6 maanden

+ 1 meer risico

Inspira Technologies Oxy B.H.N. Ltd. Concurrenten

Neuronetics

NasdaqGM:STIM

US$29.4m

Vaso

OTCPK:VASO

US$22.7m

Femasys

NasdaqCM:FEMY

US$25.2m

IRIDEX

NasdaqCM:IRIX

US$29.4m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Inspira Technologies Oxy B.H.N
Historische aandelenkoersen
Huidige aandelenkoers	US$1.38
52 Week Hoogtepunt	US$2.49
52 Week Laag	US$0.76
Bèta	2.09
11 maand verandering	2.22%
3 maanden verandering	23.21%
1 Jaar Verandering	35.29%
33 jaar verandering	-54.15%
5 jaar verandering	n/a
Verandering sinds IPO	-70.95%

Recent nieuws en updates

Recent updates

Inspira Technologies reports 1H results

Aug 11

Inspira stock soars 71% on developing non-invasive optical blood sensor Hyla

Jul 06

Rendement voor aandeelhouders

	IINN	US Medical Equipment	US Markt
7D	7.8%	1.2%	2.0%
1Y	35.3%	22.6%	32.4%

Rendement versus industrie: IINN overtrof de US Medical Equipment industrie, die het afgelopen jaar een rendement 22.6 % opleverde.

Rendement versus markt: IINN overtrof de US markt, die het afgelopen jaar een rendement opleverde van 32.4 %.

Prijsvolatiliteit

Is IINN's price volatile compared to industry and market?
IINN volatility
IINN Average Weekly Movement	6.5%
Medical Equipment Industry Average Movement	8.0%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: IINN heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van IINN is het afgelopen jaar gedaald van 12% naar 6%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2018	40	Dagi Ben-Noon	inspira-technologies.com

Inspira Technologies Oxy B.H.N. Ltd., een bedrijf gespecialiseerd in medische apparatuur, houdt zich bezig met onderzoek, ontwikkeling, productie en marketing van eigen levensondersteuningstechnologie voor de behandeling van acuut respiratoir falen. Het belangrijkste product is het INSPIRA apparaat met verhoogde ademhalingstechnologie (Gen 2), een levensondersteuning die is ontworpen om Adaptieve Bloedzuurstofvoorziening te bieden om afnemende zuurstofsaturatieniveaus te verhogen en te stabiliseren.

Inspira Technologies Oxy B.H.N. Ltd. Samenvatting

Hoe verhouden de winst en inkomsten van Inspira Technologies Oxy B.H.N zich tot de beurswaarde?
IINN fundamentele statistieken
Marktkapitalisatie	US$25.16m
Inkomsten(TTM)	-US$11.29m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-2.3x

Koers/Winstverhouding

Is IINN overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
IINN resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$11.29m
Inkomsten	-US$11.29m

Laatst gerapporteerde inkomsten

Dec 31, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.61
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde IINN op de lange termijn?

Bekijk historische prestaties en vergelijking

IINN Overzicht aandelen

Risicoanalyse

Inspira Technologies Oxy B.H.N. Ltd. Concurrenten

NasdaqGM:STIM

US$29.4m

OTCPK:VASO

US$22.7m

NasdaqCM:FEMY

US$25.2m

NasdaqCM:IRIX

US$29.4m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Inspira Technologies Oxy B.H.N. Ltd., Annual General Meeting, Dec 30, 2024

New minor risk - Financial data availability

Inspira Technologies Oxy B.H.N. Ltd. Announces Development of New Disposable Kit with Built-In Performance Monitoring Mechanism

Inspira Secures Second U.S. Patent Approval for Orbiting Blood Oxygenation Delivery System

Independent Chairman of the Board notifies of intention to sell stock

Inspira Technologies OXY B.H.N. Ltd. Announces FDA Listing and Market Readiness of New Product

Recent updates

Inspira Technologies Oxy B.H.N. Ltd., Annual General Meeting, Dec 30, 2024

New minor risk - Financial data availability

Inspira Technologies Oxy B.H.N. Ltd. Announces Development of New Disposable Kit with Built-In Performance Monitoring Mechanism

Inspira Secures Second U.S. Patent Approval for Orbiting Blood Oxygenation Delivery System

Independent Chairman of the Board notifies of intention to sell stock

Inspira Technologies OXY B.H.N. Ltd. Announces FDA Listing and Market Readiness of New Product

Inspira Technologies OXY B.H.N. Introduces the INSPIRA Cardi-ART, Aiming to Provide Oxygen to the Brain During Cardiac Arrest

New major risk - Shareholder dilution

Inspira Technologies OXY B.H.N. Ltd. Receives Israeli Regulatory Approval for the INSPIRA ART100 System

Inspira™ Introduces Advanced Life Support Solutions to Key International Leaders at the Annual iECOs Conference in Israel

Inspira™ Introduces Advanced Life Support Solutions to Key International Leaders at the Annual iECOs Conference in Israel

Inspira™ Announces Start of Production of the Inspira™ Art100

Price target increased by 44% to US$13.00

Inspira™? and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth Causes Bloodstream Infections

Inspira™ Technologies Oxy B.H.N. Ltd. Announces Program to Pioneer the Applicable Use of the INSPIRA™ ART100 Device for an Artificial Womb

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Inspira Technologies OXY B.H.N. Ltd. Announces AMAR Regulatory Submission of the INSPIRA™ ART100, to Enter the Southeast Asia and South American Markets

Inspira Releases New Data Demonstrating Superiority of its Core Technology, Across Key Endpoints of HMSS Indicator

Inspira Technologies OXY B.H.N. Ltd. Introduces High-End Platform for Bio-Mimicking Blood parameters for Development and Testing of Core Technologies

Inspiratm Technologies OXY B.H.N. Ltd. Receives First Ever U.S. Patent Approval for an Orbiting Blood Oxygenation Delivery System

New minor risk - Share price stability

Inspira Technologies Oxy B.H.N. Ltd. Announces Plans to Launch and Target Single-Use Disposable Blood Oxygenation Kit for A New Disposable Perfusion Market Opportunity

Inspira Technologies Oxy B.H.N. Ltd. has completed a Follow-on Equity Offering in the amount of $3.88 million.

Inspira Technologies Oxy B.H.N. Ltd. has filed a Follow-on Equity Offering in the amount of $3.88 million.

Inspira Technologies Oxy B.H.N. Ltd. has filed a Follow-on Equity Offering in the amount of $3.88 million.

Inspira Technologies OXY BHN Ltd. Announces 95% Accuracy Results for HYLA™? Blood Sensor, Planning FDA Submission for Clearance in 2024

Inspira Technologies Oxy B.H.N. Ltd. Announces Appointment of Dan Gorfil to its Medical Advisory Board

Inspira Technologies Oxy B.H.N. Ltd., Annual General Meeting, Dec 27, 2023

Inspira Technologies Oxy B.H.N. Ltd. Announces Israeli Innovation Authority Grant for New VORTX Disposable Blood Oxygenation Technology

Inspira Technologies OXY BHN Ltd. Announces the Grant of an Additional Patent by the U.S. Patent and Trademark Office for its Respiratory Medical Device, the INSPIRAART500

Inspira Technologies Unveils the Inspira™ Art Line of Medical Devices At the World's Largest Extracorporeal Life Support Conference

Inspira™? Announces 510(k) FDA Submission of INSPIRA™? ART100 Towards Commercialization

Inspira Technologies Appoints Dr. Nir as Chief Medical Officer

Inspira Technologies Oxy B.H.N. Ltd. to Reveal the New ALICE Device at the World's Largest Extracorporeal Life Support Conference

Inspira™ Technologies OXY B.H.N. Ltd. Develops the VORTX™ Blood Oxygenator, a Unique Technology for Saturating Blood With Oxygen and Removing Carbon Dioxide

Inspira(TM) Technologies Receives Approval from Sheba Medical Center to Conduct Clinical Study of the HYLA(TM) Blood Sensor

Inspira Technologies Receives Patent by U.S. Patent Office for the INSPIRA ART System's Convertible Dual Lumen Cannula Device and Method of Use

Inspira Technologies Oxy B.H.N. Ltd. Begins Manufacturing of the ALICE™ CPB Device, ahead of planned 2023 FDA submission

Less than half of directors are independent

Inspira Technologies Oxy B.H.N. Ltd. Receives Patent by the Israeli Patent Office for Key Safety Component for the INSPIRATM ART System

Chairman of the Board notifies of intention to sell stock

Inspira Technologies Oxy B.H.N. Ltd., Annual General Meeting, Oct 18, 2022

Inspira™ Technologies Performed HYLA™ Blood Sensor In-Vivo Study, in Preparation of Planned Human Studies

Inspira Technologies Oxy B.H.N. Ltd. Announces Changes in Management

Inspira Technologies reports 1H results

Inspira™ Technologies Reveals Next Generation Liby™ ECMO

Inspira Technologies Develops A Non-Invasive Blood Sensor

Inspira stock soars 71% on developing non-invasive optical blood sensor Hyla

Chairman of the Board notifies of intention to sell stock

Less than half of directors are independent

Inspira Technologies Appoints Daniella Yeheskely-Hayon as the New Chief Technology Officer

Inspira Technologies Oxy B.H.N. Ltd. Lists a Component of its ART and ECLS Systems on the U.S. Food and Drug Administration Class I 510(K) Exempt List

Inspira Technologies Oxy B.H.N. Ltd. Files A Pct Patent Application for Its Flagship Art Device and Proprietary Method of Use to Minimize the Need for Mechanical Ventilation

Inspira Technologies Oxy B.H.N. Ltd. has completed an IPO in the amount of $16.029091 million.

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Inspira Technologies Oxy B.H.N. Ltd. Samenvatting

0.0x